Search results
US FDA approves expanded use of Bristol Myers' cancer cell therapy
Reuters· 24 hours agoThe Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be...
...Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma -...
Benzinga· 6 hours agoThis indication is approved under accelerated approval based on response rate and duration of...
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
Morningstar· 11 hours agoBreyanzi, which was already approved in the U.S. for the treatment of relapsed or refractory large B-cell lymphoma ...
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Zacks via Yahoo Finance· 9 hours agoBristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 5 hours agoThis indication is approved under accelerated approval based on response rate and duration of...
Earnings call: Fate Therapeutics reports on clinical progress and finances By Investing.com
Investing.com· 3 days agoThe company's FT819 CAR T-cell therapy showed promise for B-cell-mediated autoimmune diseases, with...
Variations in “ancient” immune cells linked to | Newswise
Newswise· 5 days agoLed by Assistant Professor Anand Jeyasekharan, the study focused on a specific type of immune cells...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day agoPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin ...
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 7 days agoIn September last year, Kite published Phase II data for Yescarta (axicabtagene ciloleucel) for...
Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcr
Guru Focus· 4 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Allogene Therapeutics Inc (ALLO, Financial) has expanded its market opportunity in